Authors: DEVOOGT HJ STUDER U SCHRODER FH KLIJN JG DEPAUW M SYLVESTER R

Citation: Hj. Devoogt et al., MAXIMUM ANDROGEN BLOCKADE USING LHRH AGONIST BUSERELIN IN COMBINATIONWITH SHORT-TERM (2 WEEKS) OR LONG-TERM (CONTINUOUS) CYPROTERONE-ACETATE IS NOT SUPERIOR TO STANDARD ANDROGEN DEPRIVATION IN THE TREATMENT OF ADVANCED PROSTATE-CANCER - FINAL ANALYSIS OF EORTC GU GROUP TRIAL-30843, European urology, 33(2), 1998, pp. 152-158

Authors: KURTH K TUNN U AY R SCHRODER FH PAVONEMACALUSO M DEBRUYNE F TENKATE F DEPAUW M SYLVESTER R ESSED E CAUBERGH RV HOEKSTRA JW DEVOOGT HJ NEWLING DWW DEREIJKE TM MENSINK HJA GROEN JM JAKSE G LEISINGER HJ RICHARDS B ADIB RA ROBINSON M DENIS L BOUFFIOUX C SCHULMAN C CARPENTIER PJ

Citation: K. Kurth et al., ADJUVANT CHEMOTHERAPY FOR SUPERFICIAL TRANSITIONAL-CELL BLADDER-CARCINOMA - LONG-TERM RESULTS OF A EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER RANDOMIZED TRIAL COMPARING DOXORUBICIN, ETHOGLUCID AND TRANSURETHRAL RESECTION ALONE, The Journal of urology, 158(2), 1997, pp. 378-384

Authors: KLIJN JGM DEVOOGT HJ STUDER UE SCHRODER FH SYLVESTER R DEPAUW M

Citation: Jgm. Klijn et al., SHORT-TERM VERSUS LONG-TERM ADDITION OF CYPROTERONE-ACETATE TO BUSERELIN THERAPY IN COMPARISON WITH ORCHIECTOMY IN THE TREATMENT OF METASTATIC PROSTATE-CANCER, Cancer, 72(12), 1993, pp. 3858-3862